Iridex Issues Recall of TruFocus LIO Premiere Laser Indirect Ophthalmoscope

March 2, 2018: By Jon Swedien

Iridex has initiated a voluntary recall of its TruFocus LIO Premiere laser indirect ophthalmoscope.

The Mountain View, California, company announced the recall Feb. 23, after receiving reports of three adverse events during procedures using the laser accessory. Patients experienced permanent damage to the eye, including focal cataracts and iris burns, Iridex said.

The LIO is a head-mounted indirect ophthalmoscope that connects to an Iridex laser console and is used to view and perform laser treatments.

Customers should not use TruFocus LIO Premieres with part numbers 87300, 87301, 87302, 87303, and 87304, Iridex said. The company said there are 104 units at customer sites worldwide.

Iridex said it is notifying its distributors and customers via FedEx and is arranging for return of all recalled products. The company said it has notified the US FDA of the action.

Recalled products were manufactured from May 26, 2017, to Nov. 6, 2017, and distributed from June 5, 2017, to Jan. 29, 2018, the company said.

After the recall, Iridex revised its preliminary financial results for Q4-2017 and the full year.

Iridex’ total revenues for Q4-2017 are now expected to be between $10.2 million to $10.3 million. Iridex had expected the quarter’s total revenues to range from $11 million to $11.1 million.

The company’s total revenues for 2017 are expected to range between $41.5 million and $41.6 million after the recall. Previously, the company expected its 2017 revenues to range between $42.3 million and $42.4 million.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT